Transmembrane protein 213 (TMEM213)

Transmembrane protein 213 (TMEM213) is a poorly characterized integral membrane protein. Experimental evidence confirms its localization primarily in early endosomes, with a signal peptide on its N-terminus and the N-terminus facing the cytoplasm[1][2][3]. TMEM213 is membrane-bound and expressed at low levels in certain cancers, notably clear cell Renal Cell Carcinoma (ccRCC), where its downregulation on mRNA level is observed[1][3]. While the exact biological function of TMEM213 is not fully established, overexpression studies suggest that TMEM213 may contribute to processes such as glycosylation, regulation of vasculature, cell adhesion, epithelial cell proliferation, and modulation of the adaptive immune response[1][3]. Notably, potentially damaging mutations in TMEM213 have been identified in ccRCC, suggesting a possible but as yet undefined role in carcinogenesis[1][2][3]. There are currently no identified drugs that specifically target TMEM213, and it is not considered a defined therapeutic target at this time. Its molecular and biological functions, as well as clinical implications, require further study before any clinical targeting strategy can be established[1][3].

Other names

TMEM213transmembrane protein 213